Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy

Pharmacotherapy

Volumn 24, Issue 11, 2004, Pages 1546-1553

  Bagheri, Haleh ^a   Fouladi, Atoussa ^a   Barange, Karl ^b   Lapeyre Mestre, Maryse ^a   Payen, Jean Louis ^b   Montastruc, Jean Louis ^a   Vinel, Jean Pierre ^b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Adverse drug reactions; Hepatitis C; Peginterferon alfa 2b; Pharmacovigilance

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BACKACHE; BLEEDING; COHORT ANALYSIS; COMORBIDITY; CONCENTRATION LOSS; CONJUNCTIVITIS; CONSTIPATION; COUGHING; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; EPIGASTRIC PAIN; FACE EDEMA; FEMALE; FLU LIKE SYNDROME; FLUSHING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEART PALPITATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHYROIDISM; HYPOTHYROIDISM; INFECTION; IRRITABILITY; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOUTH ULCER; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYALGIA; NEUTROPENIA; PHOTOSENSITIVITY DISORDER; SKIN DISEASE; SLEEP DISORDER; SMELLING DISORDER; TASTE DISORDER; THROAT DISEASE; THROMBOCYTOPENIA; URTICARIA; VISUAL IMPAIRMENT; WEIGHT REDUCTION;

ADULT; AGED; ANTIVIRAL AGENTS; CARDIOVASCULAR DISEASES; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 7044224349     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.16.1546.50947     Document Type: Article

References (14)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
3. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994;10:115-50.
4. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
5. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
6. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-44.
7. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-64.
8. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-9.
9. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
10. Asselah T. Chronic hepatitis C: what to do if the first treatment failed? Gastroenterol Clin Biol 2002;26:B50-9.
11. Pawlotsky JM. Management of patients with hepatitis C virus infection: virological tests. Gastroenterol Clin Biol 2002;26:B180-7.
12. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
13. Palmon R, Koo BC, Shoultz DA, Dieterich DT. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29:340-5.
14. Maier I, Wu GY. Hepatitis C and HIV co-infection: a review. World J Gastroenterol 2002;8:577-9.